Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

AKT1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

AKT1 overexpression (3)

AKT1 underexpression (0)

AKT1 overexpression (3)

AKT1 underexpression (0)

›

AKT1 mutation	Triple Negative Breast Cancer	AKT1 mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
AKT1 mutation	Colorectal Cancer	AKT1 mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
AKT1 mutation	Breast Cancer	AKT1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
AKT1 mutation	Endometrial Cancer	AKT1 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
AKT1 mutation	Solid Tumor	AKT1 mutation	Solid Tumor	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3
AKT1 mutation	Prostate Cancer	AKT1 mutation	Prostate Cancer	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D	capivasertib Sensitive: D – Preclinical capivasertib Sensitive : D